Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Identification of Malignant Pancreatic Cysts May Lower Cancer Risk

By LabMedica International staff writers
Posted on 25 Jun 2010
A new study has identified candidate biomarkers for the diagnosis of pancreatic cystic neoplasms, helping clinicians predict whether the cysts are benign or are precursors to invasive cancer. More...


Researchers at the University of Michigan (Ann Arbor, USA), Indiana University (Purdue, USA), and the Van Andel Research Institute (VARI, Grand Rapids, MI, USA) used a novel antibody-lectin sandwich microarray method to measure the protein expression and glycosylation of mucin (MUC)1, MUC5AC, MUC16, carcinoembryonic antigen, and other proteins implicated in pancreatic neoplasia in cyst fluid samples. A total of 53 cyst fluid samples were obtained from patients with mucinous cystic neoplasms, intraductal papillary mucinous neoplasms, serous cystadenomas, or pseudocysts, with confirmation of histologic diagnosis at surgical resection.

The results showed that the detection of a glycan variant on MUC5AC discriminated mucin-producing cystic tumors (mucinous cystic neoplasms and intraductal papillary mucinous neoplasms) from benign cystic lesions (serous cystadenomas and pseudocysts) with 78% sensitivity at 80% specificity; when used in combination with cyst fluid CA 19-9, the results were even higher, with a sensitivity of 87% at 86% specificity. The researchers also reported that the biomarkers performed better than cyst fluid carcinoembryonic antigen. The study was published in the May 2010 issue of Annals of Surgery.

"Because of the difficulty in detecting pancreatic cancer in its early stages, most cancers are advanced at the time of diagnosis and recur after removal of the tumor,” said lead author Brian Haab, Ph.D., a senior scientific investigator at VARI. "These results demonstrate the value of glycan variants for biomarker discovery and suggest that these biomarkers could greatly enhance the accuracy of differentiating pancreatic cystic tumors.”

The most common and deadly form of pancreatic cancer, pancreatic ductal adenocarcinomas, develops from three types of cysts. Moreover, although the most prevalent type is too small to be detected visually, cystic lesions of the pancreas are increasingly being recognized due to widespread use of high-resolution abdominal imaging. This situation presents an opportunity to intervene prior to malignant progression; however, effective implementation of this strategy has so far been hampered by difficulties in clearly distinguishing between cystic lesions with no malignant potential and those with malignant potential.

Related Links:

University of Michigan
Indiana University
Van Andel Research Institute



New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The method that profiles DNA methylation in cell-free DNA from a single blood sample to detect disease signals system-wide (photo courtesy of Shutterstock)

cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample

Early, accurate detection of cancer and organ disease remains limited by cost, reliance on targeted mutation assays, and uncertainty about the signal’s tissue of origin. Many liquid biopsy approaches require... Read more

Immunology

view channel
Image: Mycobacterium tuberculosis bacteria seen with a scanning electron microscope (Credit: CDC PHIL)

Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection

Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more

Pathology

view channel
Image: Spatial characterization of immune–tumor interactions and treatment response across SCLC and extended phenotype models (Cristian Barrera et al, npj Precision Oncology (2026). DOI: 10.1038/s41698-025-01225-9)

AI Pathology Tool Predicts Chemotherapy Response in Small Cell Lung Cancer

Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.